calcium channel blocker
Muscle cells in your blood vessels and heart need calcium flowing in to contract, like a signal telling them to squeeze. A calcium channel blocker partly closes the doorways that let calcium in, so the muscle squeezes less forcefully. Vessels relax and widen, blood pressure falls, and the heart's workload eases.
The targets are voltage-gated L-type calcium channels in the membranes of vascular smooth muscle and cardiac cells. The drugs bind these channels and reduce calcium entry; because they prefer channels that are open or inactivated, they act most where cells are firing frequently.
There are three chemically distinct families with different emphasis. The dihydropyridines (such as amlodipine and nifedipine) act mainly on blood vessels and end in 'dipine'; the phenylalkylamine verapamil and the benzothiazepine diltiazem act more on the heart, slowing rate and conduction. The shared dihydropyridine ring is the defining pharmacophore of the largest family.
An honest caveat: vessel-selective dihydropyridines can cause ankle swelling and flushing, while the heart-acting agents can slow the heart too much, so the family is matched to the clinical goal.
Amlodipine, a long-acting dihydropyridine, relaxes arteries with little direct effect on heart rate, while verapamil's different scaffold makes it act chiefly on the heart's conduction.
Different chemical families steer the same channel-blocking action to vessels or heart.
The three families bind overlapping but distinct sites on the same L-type channel, a neat example of different scaffolds tuned to the same target for different therapeutic effects.